GSK (LON:GSK) Second Quarter 2024 Results
Key Financial Results
- Revenue: UK£7.88b (up 9.8% from 2Q 2023).
- Net income: UK£1.17b (down 28% from 2Q 2023).
- Profit margin: 15% (down from 23% in 2Q 2023).
- EPS: UK£0.29 (down from UK£0.40 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
GSK Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 5.2%. Earnings per share (EPS) missed analyst estimates by 15%.
Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Pharmaceuticals industry in the United Kingdom.
Performance of the British Pharmaceuticals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 3 warning signs for GSK you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About LSE:GSK
GSK
Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
High growth potential and good value.
